Pre-implantation genetic diagnosis (PGD) is the general name given to the tests performed on the embryo prior to transfer to the mother's uterus.
This test aims to detect and prevent the transmission of serious genetic or chromosomal diseases to the future baby. This technique ensures that babies are born free of these genetic diseases.
This technique consists of performing an embryo biopsy in which some cells are removed from the developing embryo (around day 5 of its growth).
Genetic material is taken from inside these cells to be analysed to identify whether the disease in question is present. This allows us to select an embryo free of the disease and transfer it to the future mother.
DIAGNOSIS
Pre-implantation genetic diagnosis or PGD has been given different names depending on the problem to be studied. Since 2017 there has been a new consensus on terminology among the world's leading assisted reproductive technology associations.
Thus, the term PGT (Preimplantation Genetic Testing) is used, to which the initials of the type of anomaly studied are added.
This is used to detect numerical anomalies (aneuploidy).
The normal number of chromosomes is 23 pairs, 22 plus the sex pair: XX or XY. In Down's syndrome, chromosome number 21 appears triplicated.
Other common aneuploidies in live-born babies are: trisomy 18 (Edwards' syndrome), trisomy 13 (Patau's syndrome), Turner's syndrome (in females, total or partial absence of an X sex chromosome) or Klinefelter's syndrome (males born with an extra X chromosome).
There are several types of structural alterations, either with or without gain/loss of genetic material: deletions, inversions, translocations, duplications, insertions or rings.
Some of these chromosomal abnormalities compromise the viability of the embryo (non-implantation or miscarriage) and others would result in a disease in the future baby.
It studies hereditary diseases due to mutation or alteration in the DNA sequence of a certain gene.
Also known as Mendelian inherited diseases, they can be of 3 types: Autosomal recessive diseases, autosomal dominant diseases and X-linked diseases.
This new system allows, in addition to all the advantages of traditional PGT-A, to know the origin of the aneuploidy, that is, whether it comes from the female gamete or the male gamete, which makes it possible to decide whether to resort to egg or sperm donation.
In addition, it allows us to confirm whether the embryo has indeed been made with the egg and sperm of the couple and to recover true embryos with two pronuclei, a type of embryo that can be valid for transfer and that are usually discarded. In this way, extra embryos can be obtained for treatment.
PATIENTS
Dr. Elisa Pérez, from IVF-Life Donostia
FIND ANSWERS TO YOUR QUESTIONS
Chromosomal abnormalities can be divided into two types: numerical and structural.
These diseases, also known as Mendelian inherited diseases, can be of three types:
Autosomal recessive disease: occurs when two copies (maternal and paternal) of a mutated gene coincide in the genome of the affected person. In this case, the parents are carriers of a copy without having the disease. The chance of having a child who develops the disease if both parents are carriers is 25%. Examples of inherited diseases are cystic fibrosis and spinal muscular atrophy.
Autosomal dominant disease: in this case only one copy of the defective gene is needed for a person to develop an autosomal dominant disease. The probability of offspring inheriting the disease from a parent with the disease is 50%. Examples of autosomal dominant diseases are Huntington's disease and Steinert's myotonic dystrophy.
X-linked disease: occurs when the mutated gene is located on the X chromosome and are diseases that can be transmitted either dominantly or recessively. For example, haemophilia A and Fragile X syndrome are inherited diseases.
PGT can help select embryos without genetic abnormalities, but it does not increase IVF success rates in all cases nor does it guarantee pregnancy.
The use of PGT is not necessary in all cases and should be determined medically based on each patient’s individual factors.
WHAT OUR PATIENTS SAY